Wan-Yin Chan
Allergy & Immunology · Orange, CANPI 1932391471
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,072 of the $19,356 with a category attached, or 62.4%. 31 manufacturers reported payments, led by CSL Behring at 46.4% of the total. 2025 is the largest year on record at $5,787, 2.6 times the $2,222 reported in 2019.
Across 490 payments — averaging $39.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$9K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$2K
- Sanofi$1K
- Amgen$458
- plus $3K from 25 others
Across 7 payments — averaging $17,726 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amphastar Pharmaceuticals, Inc.$90K
- AstraZeneca$27K
- Novartis$7K
What the payments were for
- Consulting fees$6,63834%
- Travel & lodging$3502%
- Food & beverage$12,07262%
- Education$2962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 100 | $8,974 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $2,593 |
| Regeneron Healthcare Solutions, Inc. | 50 | $1,625 |
| AstraZeneca | 57 | $1,600 |
| Sanofi | 85 | $1,373 |
| Amgen(2 entities) | 21 | $458 |
| Genentech USA, Inc. | 10 | $353 |
| Optinose US, Inc. | 18 | $308 |
| Novartis | 12 | $306 |
| GSK | 13 | $246 |
| Pfizer | 10 | $209 |
| Shire North American Group Inc | 10 | $191 |
| AbbVie | 5 | $132 |
| Grifols USA, LLC | 6 | $125 |
| Blueprint Medicines Corporation | 1 | $120 |
| Pharming Healthcare, Inc. | 2 | $112 |
| Kaleo, Inc. | 4 | $84 |
| Incyte Corporation | 3 | $71 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Boehringer Ingelheim | 3 | $55 |
| Azurity Pharmaceuticals, Inc. | 2 | $53 |
| Octapharma USA, Inc. | 2 | $53 |
| Biocryst US Sales Co., LLC | 2 | $45 |
| LEO Pharma Inc. | 2 | $43 |
| Ionis Pharmaceuticals, Inc. | 1 | $34 |
| Greer Laboratories, Inc. | 1 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Organon | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,356 in reported general payments places this provider in the 85th percentile of 426 allergy & immunology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $46,205 |
| XolairOmalizumab | 12 | $39,887 |
| Montelukast Sodium | 15 | $113 |
| Fluticasone Propionate | 17 | $112 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Orange
- Donald LevyOrange$207K
- Raffi TachdjianSanta Monica$3.7M
- Bob GengSan Diego$3.3M
- Vinay MehtaLaguna Niguel$1.3M
- Andrew WhiteSan Diego$752K
- Marc RiedlSan Diego$725K
- Katharine WoessnerSan Diego$581K
- Brian Modenala Jolla$453K
- Heena Shah PatelUpland$428K
- Jacob OffenbergerGranada Hills$419K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.